Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

Priscilla Tsondai, MD, MPH, breaks down top care gaps as opportunities for care improvement.

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.